Screener
Arcus Biosciences RCUS Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Arcus Biosciences’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001724521-26-000044
FAQ
- What is Arcus Biosciences's total equity?
- Arcus Biosciences (RCUS) reported total equity of $464M in Q2 2026.
- How has Arcus Biosciences's total equity changed year-over-year?
- Arcus Biosciences's total equity decreased by 15.5% year-over-year, from $549M to $464M.
- What is the long-term trend for Arcus Biosciences's total equity?
- Over 5 years (2020 to 2025), Arcus Biosciences's total equity has grown at a 4.7% compound annual growth rate (CAGR), from $502M to $631M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Arcus Biosciences's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude